Τίτλος:
CD56 expression in multiple myeloma: Correlation with poor prognostic
markers but no effect on outcome
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
CD56 or neural cell adhesion molecule (NCAM) is a membrane glycoprotein
expressed on neural cells, muscle tissues and myeloma cells. Expression
of CD56 has been studied in patients with multiple myeloma (MM) with
controversial results. The scope of this study was to examine the
expression of CD56 in MM patients at diagnosis and investigate its
association with clinicopathologic parameters. We retrospectively
collected and analyzed data from 109 patients with MM diagnosed over the
last decade (January 2010 to June 2020). Expression of CD56 was assessed
by immunohistochemistry in bone marrow biopsies and investigated its
association with a variety of clinicopathological parameters. For the
statistical analysis chi(2) test and Mann-Whitney U tests were used to
compare categorical and continuous variables in CD56+ and CD56-
patients, respectively. Statistical analysis was performed using SPSS
21.0 for Windows (SPSS, Chicago, IL). Based on the expression of CD56
the patient population was divided to CD56+ patients and CD56- patients;
Sixty-eight patients were CD56 + and 41 patients were CD56-. Absence of
CD56 expression was associated with unfavorable prognostic parameters
such as elevated lactate dehydrogenase (LDH) and beta 2-microglobulin
levels, advanced stage according to the International Staging System
(ISS) and clonal bone marrow plasma cell infiltration >= 60%, but no
effect on outcome, while the expression of CD56 was associated with well
differentiated neoplastic plasma cells. Our study confirmed that lack of
CD56 expression is a possible marker of poor prognosis in patients with
MM. The detection of CD56 expression by either immunohistochemistry or
flow cytometry is simple and cheap, and it could be incorporated in
future prognostic or predictive scores. Prospective studies are needed
in order to evaluate the role of expression of CD56 as a predictive
biomarker in the era of novel regimens.
Συγγραφείς:
Koumpis, Epameinondas
Tassi, Iliana
Malea, Theodora and
Papathanasiou, Konstantina
Papakonstantinou, Ioannis
Serpanou,
Anastasia
Tsolas, Evangelos
Kapsali, Eleni
Vassilakopoulos,
Theodoros P.
Papoudou-Bai, Alexandra
Hatzimichael, Eleftheria
Περιοδικό:
PATHOLOGY RESEARCH AND PRACTICE
Λέξεις-κλειδιά:
CD56; NCAM; Prognostic factor; Multiple myeloma
DOI:
10.1016/j.prp.2021.153567
